(0.08%) 5 250.50 points
(0.01%) 39 644 points
(0.16%) 18 284 points
(0.12%) $78.35
(1.24%) $2.28
(-0.87%) $2 354.30
(-0.42%) $28.39
(-0.01%) $1 007.10
(-0.02%) $0.928
(0.33%) $10.87
(0.02%) $0.799
(-0.94%) $91.80
@ $27.97
Issued: 14 Feb 2024 @ 15:13
Return: -8.12%
Previous signal: Feb 14 - 13:43
Previous signal:
Return: 2.04 %
Live Chart Being Loaded With Signals
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology...
Stats | |
---|---|
Today's Volume | 397 446 |
Average Volume | 667 403 |
Market Cap | 1.31B |
EPS | $0 ( 2024-05-08 ) |
Next earnings date | ( $-0.740 ) 2024-05-21 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.96 |
ATR14 | $0.0290 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Bizily Scott | Sell | 1 250 | Stock Option (Right To Buy) |
2024-04-16 | Bizily Scott | Sell | 500 | Stock Option (Right To Buy) |
2024-04-16 | Bizily Scott | Buy | 1 250 | Common Stock |
2024-04-16 | Bizily Scott | Buy | 500 | Common Stock |
2024-04-16 | Bizily Scott | Sell | 1 750 | Common Stock |
INSIDER POWER |
---|
31.03 |
Last 99 transactions |
Buy: 3 571 023 | Sell: 1 811 773 |
Volume Correlation
4D Molecular Correlation
10 Most Positive Correlations | |
---|---|
FCBP | 0.889 |
RDCM | 0.883 |
KURA | 0.876 |
GNTX | 0.873 |
SANM | 0.872 |
PXLW | 0.871 |
USMC | 0.869 |
LRGE | 0.869 |
ESPO | 0.868 |
FWRG | 0.867 |
10 Most Negative Correlations | |
---|---|
DISH | -0.853 |
RTPY | -0.85 |
LSAQ | -0.849 |
MMAT | -0.846 |
TKLF | -0.843 |
CSSEP | -0.843 |
DSWL | -0.841 |
ISDX | -0.838 |
GSM | -0.832 |
ZIONP | -0.827 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
4D Molecular Correlation - Currency/Commodity
4D Molecular Financials
Annual | 2023 |
Revenue: | $20.72M |
Gross Profit: | $14.97M (72.26 %) |
EPS: | $-2.58 |
FY | 2023 |
Revenue: | $20.72M |
Gross Profit: | $14.97M (72.26 %) |
EPS: | $-2.58 |
FY | 2022 |
Revenue: | $3.13M |
Gross Profit: | $-751 000 (-24.00 %) |
EPS: | $-3.12 |
FY | 2021 |
Revenue: | $18.04M |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-11.09 |
Financial Reports:
No articles found.
4D Molecular
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators